Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy

Published:2022-11 Issue:11 Volume:3 Page:100420
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Pataer Apar,Weissferdt Annikka,Correa Arlene M.,Vaporciyan Ara A.,Sepesi Boris,Heymach John V.,Berezowska Sabina,Cascone Tina,Swisher Stephen G.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Current status and future perspectives on neoadjuvant therapy in lung cancer;Blumenthal;J Thorac Oncol,2018

2. The role of neoadjuvant trials in drug development for solid tumors;Funt;Clin Cancer Res,2016

3. Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches;Uprety;J Thorac Oncol,2020

4. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial;Cascone;Nat Med,2021

5. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint;Hellmann;Lancet Oncol,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations;ESMO Open;2024-08

2. Immune checkpoint inhibition in early-stage non-small cell lung cancer;Lung Cancer;2024-07

3. Immuntherapien beim frühen NSCLC;Im Fokus Onkologie;2024-06-27

4. Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study;Oncology Letters;2024-06-13

5. Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy;Advances in Anatomic Pathology;2024-04-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3